Los Angeles Times, January 4, 2011

A therapy derived from human embryonic stem cells may help millions of Americans battle a common form of blindness. Advanced Cell Technology Inc. said Monday that it has received a green light from the U.S. Food and Drug Administration to begin a clinical trial to test its therapeutic cells as a treatment for dry age-related macular degeneration. The company plans to enroll a dozen patients in a Phase I/II trial, which would primarily test the safety of the cells and whether they are well-tolerated by patients.
Facebook icon
LinkedIn icon
Twitter icon